Isofol appoints Gustaf Albèrt as Chief Financial Officer
Isofol Medical AB (publ) has recruited Gustaf Albèrt as Chief Financial Officer. With extensive experience from leading financial positions, Albèrt […]
Corporate Information
Isofol announces that Modufolin® as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities
Isofol Medical AB (publ) announces that results from the clinical ISO-MTX-003 study suggest that Modufolin® as a rescue therapy, in
Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin® for treatment of metastatic colorectal cancer
Isofol Medical AB (publ) announces the completion of a successful Type-C meeting with the FDA in preparation for the pivotal
From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin® in patients with metastatic colorectal cancer
Isofol Medical AB (publ), a clinical oncology company, announces that the initial indications of Modufolin® efficacy in the ISO-CC-005 study
Isofols appoints Sven Erickson as Chief Commercial Officer
In preparation for partnering negotiations with pharma companies Isofol Medical AB (publ) announces the appointment of Sven Erickson as Chief
Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin®
Isofol Medical AB (publ) announces that Professor Sten Nilsson, an experienced industry advisor and principal investigator, and Dr. Alain Herrera,
Isofol announces that an abstract about Modufolin® in osteosarcoma treatment will be presented at ESMO 2017
Isofol Medical AB (publ) announces that an abstract about Modufolin® has been accepted to be presented at ESMO 2017, taking
Scrip Intelligence, a leading source of news and strategic analysis for the global pharmaceutical industry, publish article about Isofol Medical
John Davis, journalist and editor for more than 30 years, of Scrip Intelligence recently interviewed Anders Rabbe, CEO of Isofol
Isofol has enrolled and dosed its first group of patients in the IND-study ISO-FF-001
Isofol Medical AB (publ) announced today that the first six patients were enrolled and dosed in the ISO-FF-001 study. The
New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study
Isofol Medical AB (publ) announced today that academic researchers collaborating with Isofol have presented results last week at ESMO-GI which